NEXENTIS TECHNOLOGIES INC

NXTSNASDAQ

🏆 #3946 by market capUS Equity

$1.89▲ $0.01 (+0.53%)

Live

1h—

24h▲ 0.5%

7d—

14d—

30d—

1y—

🏦Market Cap

$3M

Small Cap

📈Revenue Growth (YoY)

+18.9%

Healthy

📊Gross Margin

66.2%

High

💵FCF Margin

—

⚖️P/S Ratio

13.1x

Elevated

Otter Score

Weak

No chart data available for NXTS.

Trading Snapshot

Day Range: $1.87 – $1.90
52-Week Range: $1.43 – $60.48
Volume: $6.84B
Avg Volume: $8.85B
Shares Outstanding: 1.4M
Next Earnings: Oct 7, 2026

Fundamentals Snapshot

Annual Revenue: $208,521
Last Q Revenue: $47,215
P/E Ratio: —
P/S Ratio: 13.1x
EPS (TTM): $-55.61
Dividend Yield: —

Why Investors Own NXTS

✓High-growth profile — revenue up +4.8% YoY with expanding US Equity exposure.
✓Healthy economics — 27% gross margin and 18% free-cash-flow margin.
✓New products and segments could unlock additional revenue streams.

⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

Financial Trends

Revenue (TTM)

$208,521▲ +0.1% YoY

Gross Margin (TTM)

26.7%▲ +0.1% YoY

Operating Income (TTM)

$47,334▲ +0.1% YoY

Free Cash Flow (TTM)

$37,951▲ +0.1% YoY

About NEXENTIS TECHNOLOGIES INC

Nexentis Technologies Inc., through its subsidiary, develops therapeutics related to cancer and inflammatory metabolic diseases. It operates through two segments, Biotechnology Activity and Renewable Energy Projects. The company's pipeline includes MITOLINE, an algorithm used to perform multiple sequence/ structure pairwise alignments which could then be used for generating a 3D comparative model of potentially all mitochondrial carrier proteins; cloud-based computational chemistry platform; and novel in-vitro screening platforms; and advanced 3D NSCLC tumor spheroid systems.The company was formerly known as N2OFF, Inc. and changed its name to Nexentis Technologies Inc. in February 2026. Nexentis Technologies Inc. was incorporated in 2009 and is headquartered in Ness Ziona, Israel.

🦦